PELICAN-IPC 2015-016/Oncodistinct-003: A Prospective, Multicenter, Open-Label, Randomized, Non-Comparative, Phase II Study of Pembrolizumab in Combination With Neo Adjuvant EC-Paclitaxel Regimen in…

Overview of attention for article published in Frontiers in oncology, November 2020

Altmetric Badge

Mentioned by

twitter: 1 X user

Citations

dimensions_citation: 7 Dimensions

Readers on

mendeley: 26 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 1 X post from an account with 6,528 followers.

New research: PELICAN-IPC 2015-016/Oncodistinct-003: A Prospective, Multicenter, Open-Label, Randomized, Non-Comparative, Phase II Study of Pembrolizumab in Combination With Neo Adjuvant EC-Paclitaxel Regimen in HER2-Negative Inflammatory… https://t.co/OMA

01 Jan 2021

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.